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Abstract
Adult attention-deficit/hyperactivity disorder (aADHD) has recently been better recognized and treated in many European 
countries. In spite of this development, aADHD still features as a “hidden” comorbidity, often not diagnosed even in patients 
under psychiatric treatment for other psychiatric disorders. The aim of this study was to establish the prevalence rates of 
unrecognized aADHD in academic centers providing regular psychiatric services in the Czech Republic and Hungary. In a 
population of psychiatric in-and outpatients, Adult ADHD Self-Report Scale was administered. All positively and about half 
of the negatively screened subjects were clinically interviewed and the DSM diagnosis of ADHD was determined based on 
the symptom list and Conners’ Adult ADHD Rating Scale. The estimated point prevalence rate of unrecognized comorbid 
aADHD among psychiatric in-and out patients was 6.99% (95% lower CI: 5.11, 95% upper CI 8.86) according to the DSM-
IV-TR criteria and 9.27% (95% lower CI: 7.13, 95% upper CI 11.40) according to the DSM-5 criteria. Current suicide risk 
was significantly associated with the presence of undiagnosed aADHD; however, life time suicide attempts, depression, 
dysthymia, alcohol and substance dependence, anxiety and stress related disorders were not. Further educational efforts are 
needed to improve the recognition and treatment of aADHD in adults
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Introduction
Attention-deficit/hyperactivity disorder (ADHD) is a neu-
rodevelopmental disorder, characterized with persistent and 
developmentally inappropriate level of inattention and/or 
hyperactivity and impulsivity, resulting in functional impair-
ment (Buitelaar et al. 2011). Approximately two-thirds of 
individuals diagnosed with ADHD early in their lives suffer 
from symptoms in adult age, as well; 15% of them meet full 
DSM-IV-TR (American Psychiatric Association 2000) diag-
nostic criteria and the rest is regarded as ‘ADHD in partial 
remission’ (Ramos-Quiroga et al. 2013). Typically, the most 
frequent subtype of adult ADHD (aADHD) is predominantly 
inattentive type, with associated disorganization, emotional 
dysregulation (Kooij et al. 2010).
A meta-analysis reported a 2.5% prevalence of aADHD 
based on pooled data of population-based studies (Simon 
et al. 2009). Similar number (current DSM-IV-TR aADHD 
prevalence of 2.8%) has been recently reported in a rep-
resentative WHO World Mental Health Survey across 20 
countries (Fayyad et al. 2017).
Adult ADHD is often associated with negative outcome, 
as evidenced by impaired psychosocial functioning and low 
quality of life, including poor academic and occupational 
performance, interpersonal relationships, driving skills, low 
socioeconomic status, self-esteem, or high criminality rates 
(Kooij et al. 2010; Buitelaar et al. 2011). The estimated eco-
nomic impact of aADHD in the US is $105–194 billion per 
year, the highest proportion being attributed to productiv-
ity and income loss, $87–137 billion (Doshi et al. 2012). 
Swedish register and population-based data suggest that any 
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drug treatment of aADHD may reduce criminality, serious 
traffic accidents, and even suicide rates (Lichtenstein et al. 
2012; Chang et al. 2014; Chen et al. 2014).
However, the recognition of aADHD remains poor, which 
is partly explained by the high rates of comorbidity, which 
may make the diagnosis difficult (Asherson et al. 2007, 
2014). In general, psychiatric comorbidity rates in aADHD 
can be as high as 49% for any current and 89% for any past 
DSM-IV-TR Axis I disorder, and 78.5% for at least one, and 
45% for at least two DSM-IV-TR Axis II disorders (Jacob 
et al. 2007; Sobanski et al. 2007; Cumyn et al. 2009). Spe-
cifically, compared with non-ADHD subjects, significantly 
higher rates of comorbid major depression (MD), dysthymia, 
bipolar disorder (BD), anxiety disorders, substance use dis-
orders (SUD), personality disorders (PD) were consistently 
reported in adults with ADHD (Jacob et al. 2007; Sobanski 
et al. 2007; Cumyn et al. 2009; Asherson et al. 2014; Per-
roud et al. 2014).
In a complementary manner, some authors suggested 
that undiagnosed aADHD could be a frequent comorbidity 
in patients already in treatment for at least one psychiatric 
disorder other than ADHD (Rao and Place 2011; Ginsberg 
et al. 2014). In a recent cross-sectional study conducted in 
psychiatric outpatient health care facilities in eight European 
countries, the prevalence of aADHD was estimated between 
14.2 and 19.0% (min and max values of 95% CIs of the 
prevalence values based on different definitions) (Deberdt 
et al. 2015).
The primary objective of our study was to estimate the 
prevalence of undiagnosed aADHD in both inpatient and 
outpatients of university psychiatric clinics providing “regu-
lar” care. The secondary objectives were: (1) to investigate 
the effect of different diagnostic criteria on prevalence esti-
mates of aADHD assessed in Czech and Hungarian psychi-
atric inpatient and outpatient samples, and (2) to estimate 
the rate of comorbidity with aADHD in patients already 
diagnosed with another psychiatric disorder.
Methods
The study protocol was approved by the ethics commit-
tees for the Department of Psychiatry and Psychotherapy, 
Semmelweis University in Budapest, Hungary and for the 
Prague Psychiatric Center/National Institute of Mental 
Health, Czech Republic. During the course of the study, a 
third study site (second Czech site) was added, Psychiatric 
Clinic University Hospital in Olomouc, in order to increase 
subjects’ enrollment. The change was approved by the Eth-
ics Committee.
Eligible study subjects were males and females, age of 
18–60 years, currently undergoing inpatient or outpatient 
psychiatric treatment for a DSM-IV-TR Axis I diagnosis 
other than ADHD, with capacity to sign informed consent 
form in their native language. Exclusion criteria were history 
of major neurological disorders and diagnosis of the follow-
ing psychiatric disorders: schizophrenia, cognitive disorders 
(e.g., dementia).
The study consisted of two phases: Phase I (Screening 
Phase), and Phase II (Interview Phase), described below in 
detail.
Phase I
During the Screening Phase, consecutively arriving and 
consenting patients entered the study on randomly selected 
days. The number of participants screened during a day var-
ied according to patients consent and availability. Approxi-
mately half of the negatively screened participants were 
approached for to participation in the Interview Phase of 
the study. All study subjects signed informed consent form 
prior to administration of any study procedure. A trained 
assistant distributed to the subjects the ADHD screener, 
the Adult ADHD Self-Report Scale (ASRS). ASRS is an 
18-item self-report scale, based on the symptom list of 
DSM-IV-TR, developed by the Workgroup on Adult ADHD 
in conjunction with the World Health Organization (WHO) 
(Kessler et al. 2007). Symptom frequency was measured on 
a 5-point Likert scale. In the screening phase of the study, 
the 6-question, screener version of ASRS was applied. This 
short version of ASRS was reported to have good sensitivity 
and specificity as well as predictive value for the diagnosis 
of aADHD (Kessler et al. 2005). All positively screened and 
about half of the negatively screened subjects were invited 
to further participate in the study.
Phase II
Consenting patients entered Phase II, the Interview Phase. 
During the clinical interview, in addition to demographic 
data and diagnosis of aADHD, other potential comorbid 
psychiatric disorders were assessed.
DSM‑IV‑TR symptom list
A structured clinical interview has been earlier developed 
by the authors, using the symptom list of ADHD in DSM-
IV-TR, including functional impairment and onset criteria 
(i.e., whether some of the symptoms had caused problems 
before the age of seven) as well (Bitter et al. 2010). The 
interview is comprised of two sections. The first section 
assessed the presence of ADHD in childhood and included 
20 items: 18 symptoms, as well as functional impairment 
and age of onset. The second section assessed the presence 
of aADHD based on the same items as in the first section 
(with the exclusion of age of onset, which has already been 
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collected in the first section); functional impairment (yes/
no) was established based on whether the symptoms were 
present and caused problems during the past half a year.
Clinical interview
During the clinical interview, the interviewer had 20–30 min 
to collect relevant information about the presence aADHD. 
The type of information needed to be gathered was the same 
for all the participants, but the interview was conducted in 
an open-ended fashion, while the interviewers were making 
detailed notes. The following issues had to be addressed: 
complications during pregnancy and delivery; develop-
mental deviations; family background (relationship with 
parents, siblings, brief family history); preschool nursing 
(problems with the other children, problems with the pre-
school teachers, adjustment problems); school years (studies, 
behavior, relationship with students/teachers); jobs (conflicts 
with colleagues/supervisors, frequent job and/or workplace 
changes); relationships.
Demographic and clinical characteristics
The following items were recorded and included in the 
assessment of demographic and clinical characteristics: 
age, gender, years of education, type of education, marital 
status, current DSM-IV-TR Axis I diagnosis, psychiatric 
and medical history, family history, medications taken on 
a regular basis, smoking status, handedness.
Conners’ adult ADHD rating scale (CAARS)
The CAARS 66 item self-report version (CAARS-S:L) 
developed by Conners et al. (1999) was used. CAARS 
includes four factor-derived subscales (inattention/mem-
ory problems, hyperactivity/restlessness, impulsivity/
emotional lability, problems with self-concept) and three 
DSM-IV-TR ADHD Subscales: DSM-IV-TR Inattentive 
Symptoms, DSM-IV-TR Hyperactive-Impulsive Symp-
toms, DSM-IV-TR Total ADHD Symptoms), the ADHD 
Index and the Inconsistency Index. Items are rated on a 4 
point scale (0–3).
MINI‑PLUS 5.0 structured interview
The validated Czech and Hungarian versions of MINI-
PLUS structured interview (Balázs et al. 1998; Sheehan 
et al. 1998) were applied for the assessment of lifetime and 
current DSM-IV-TR Axis I psychiatric disorders.
Table 1  Estimated prevalence 
rates adjusted for the sensitivity 
and specificity of the screener 
and for sex ratio (1:1) for the 
four diagnostic groups defined 
in our study
Total number of patients is based on the group of positively screened subjects. Differences in total number 
of patients is explained by missing data
ADHD DSM-
IV (full criteria)
ADHD 
DSM-IV 
Sx
ADHD 
DSM-IV no 
onset
ADHD DSM-5 
(full criteria)
Estimated prevalence % 6.99 13.41 9.18 9.27
SE for the estimated prevalence 0.96 0.13 0.11 0.11
95% lower CI for the estimated prevalence 5.11 10.90 7.06 7.13
95% upper CI for the estimated prevalence 8.86 15.92 11.31 11.40
Table 2  Proportion of DSM-IV ADHD “yes” and “no” diagnoses associated with the most frequent current “main” (comorbid) psychiatric dis-
orders and current suicide risk
*Generalized anxiety disorder, panic disorder, agoraphobia, social phobia, obsessive–compulsive disorder, posttraumatic stress disorder; none of 
the listed disorders yielded significant Chi-square results separately
Main comorbid psychiatric disorder (MCPD) (MCPD/total number of 
available patients)
In DSM-IV ADHD 
NO (n) %
In DSM-IV ADHD 
YES (n) %
Chi-square
DF Value P
Depression (188/438) (171) 42.86 (17) 43.59 1 0.01 0.93
Suicide risk current (38/433) (10) 54.43 (28) 73.68 1 5.21 0.02
Alcohol dependence (65/433) (59) 14.97 (6) 15.38 1 0.00 0.94
Psychoactive substance dependence (other than alcohol) (51/393) (47) 13.06 (4) 12.12 1 0.02 0.88
Anorexia (13/432) (13) 3.31 (0) 0 1 1.33 0.25
Anxiety and stress related disorders* (265/438) (239) 59.90 (26) 66.67 1 0.68 0.41
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Diagnosis of aADHD
Based on the documentation of the clinical interview, the 
study team decided whether the participant meets the criteria 
for the clinical diagnosis of adult ADHD. Based on previous 
aADHD prevalence studies (Bitter et al. 2010), modified 
diagnostic criteria were also applied to investigate the effect 
of diagnostic criteria on the prevalence estimates. Below, we 
present three modified criteria based on their relation to the 
DSM-IV-TR criteria and a fourth criterion based on DSM-5 
criteria (American Psychiatric Association 2013).
1. ‘ADHD_DSM-IV-TR’ diagnostic group: based on the 
full set of DSM-IV-TR criteria for both childhood and 
aADHD (combined, or inattentive, or hyperactive/
impulsive type) with supporting information based on 
the clinical interview.
2. ‘ADHD_No-onset’ group: based on DSM-IV-TR criteria 
for both childhood and aADHD (combined or inattentive 
or hyperactive/impulsive type), excluding onset crite-
rion.
3. ‘ADHD_Symptoms-only’ group: based on DSM-IV-TR 
symptom criterion only (6 symptoms had to be present 
out of the 9 symptoms of either inattention or hyper-
activity/impulsivity, or both) for both childhood and 
aADHD.
4. ‘ADHD_DSM-5’ diagnostic group: based on the full set 
of DSM-5 criteria for both childhood and aADHD with 
supporting information based on the clinical interview. 
The study protocol was written prior to the publication 
of DSM-5. DSM-5 criteria were added to the protocol 
after its publication.
Statistical analysis
The Statistical Analysis System for Windows (version 9.1; 
SAS Institute, Cary, NC) was used for statistical analyses. 
All statistical analyses used the alpha error level of 0.05 
(two-sided) and 95% confidence intervals. In order to deter-
mine the true population prevalence, the specificity and sen-
sitivity of the screening test was taken into consideration.
Results
Seven hundred and sixteen patients were included in the 
screening phase (Budapest: 580, Prague: 136) between 7th 
July, 2012 and 26th June, 2014. Eight patients fulfilled one 
of the exclusion criteria; thus, we report data on 708 patients 
(Tables 1, 2). Patients disposition including basic demo-
graphic data and the ASRS mean scores of the study sample, 
as well as the ‘positively screened’, ‘interviewed’ and ‘not-
interviewed’ and the ‘negatively screened’ ‘interviewed’ 
and ‘non-interviewed’ subsamples are presented in Fig. 1. 
Figure 1 also describes the row prevalence rates of the four 
predefined groups as listed above:
1. ‘ADHD_DSM-IV-TR’ diagnostic group: based on the 
full set of DSM-IV-TR criteria for both childhood and 
aADHD.
2. ‘ADHD_No-onset’ group: based on DSM-IV-TR criteria 
for both childhood and aADHD without the criterion of 
onset.
3. ‘ADHD_Symptoms-only’ group: based on DSM-IV-TR 
symptom criterion only (6 symptoms had to be present 
out of the 9 symptoms of either inattention or hyper-
activity/impulsivity, or both) for both childhood and 
aADHD.
4. ‘ADHD_DSM-5’ diagnostic group: based on the full set 
of DSM-5 criteria for both childhood and aADHD.
Discussion
Our data support earlier findings that aADHD often remains 
an undiagnosed and consequently untreated disorder even 
in patients under treatment for another psychiatric disor-
der (Deberdt et al. 2015). While the estimated point preva-
lence rates (adjusted for age and sex and for the sensitivity 
and specificity of the screener) of undiagnosed aADHD in 
the two Czech and the one Hungarian psychiatric centers 
were found to be lower than in the cited European study 
(Deberdt et al. 2015), they are still high. The European study 
reported row rates “applying DSM-IV-TR-TR or DSM-5 cri-
teria, 15.8% (95% confidence interval [CI] 14.2–17.4%) or 
17.4% (95% CI 15.7–19.0%) of patients were diagnosed with 
ADHD, respectively”, while we report adjusted prevalence 
estimations for the DSM-IV-TR group 6.99% (95% confi-
dence interval [CI] 5.11%–8.86%) and for the DSM-5 group 
9.27% (95% confidence interval [CI] 7.13%–11.40%). The 
strength of this study is that in order to improve case iden-
tification in addition to ASRS further methods were used, 
including a semistructured clinical interview, the Conners’ 
Adult ADHD Rating Scale (CAARS) and the MINI-PLUS 
5.0 Structured interview. The European study found 10% 
higher rates using DSM-5 criteria as compared to DSM-IV-
TR criteria, while our study shows a 32.6% higher rate when 
using DSM-5 criteria as compared to DSM-IV-TR criteria. 
These results are similar to those of Vitola et al. (2017), who 
found that “The use of the DSM-5 criteria results in a higher 
prevalence of ADHD when compared to those obtained by 
DSM-IV.”
We found no significant differences between the sizes of 
the subgroups with or without DSM-IV-TR aADHD in the 
investigated diagnostic groups; however, there are statisti-
cally significant differences regarding current suicide risk. 
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This finding is in line with previous studies highlighting the 
positive association between ADHD and suicidality (Bal-
azs and Kereszteny 2017). The presence of aADHD may 
be associated with more severe symptoms of the comorbid 
psychiatric disorders; however, no data were collected in 
this study to characterize the severity of comorbid disorders.
In case no childhood onset of ADHD can be identified, 
clinicians should carefully assess impairment, psychiatric 
history, and substance use before treating potential late-onset 
cases. False positive late-onset ADHD cases are common 
without careful assessment (Sibley et al. 2018). However, 
as Matte et al. (2015) pointed out about the DSM-5 adult 
ADHD criteria, “The proposed new impulsivity symptoms 
for adults do not improve ADHD diagnosis enough to over-
come potential negative effects of changing the criteria. 
However, fewer symptoms than the six-of-nine threshold 
required by DSM-IV provided the best cutoff point for iden-
tifying adults who are impaired.”
The proper diagnosis and treatment of comorbid ADHD 
and other psychiatric disorders is important, since they may 
lead to higher rates of unfavorable outcomes. Available evi-
dence suggests that ADHD is associated with earlier onset 
of comorbid disorders, such as alcoholism and “ADHD in 
combination with a comorbid disorder (depression, anxiety 
disorder, etc.) additionally increases the risk of developing 
an addiction” (Ohlmeier et al. 2008). Although the pres-
ence of comorbid psychiatric conditions with ADHD com-
plicates the treatment and results in more severe dysfunction 
and impairment (Biederman 2004), the background of the 
observed high rate of psychiatric comorbidity in ADHD is 
still an open question. (Sonuga-Barke 2005; Spencer et al. 
2007; Biederman et al. 2008; Halmoy et al. 2010).
Developmental disturbances (Sonuga-Barke 2005) as 
well as the role of overlapping symptoms and possible case 
over-identification (Halmoy et al. 2010) have already been 
suggested in the literature. Gender differences were consist-
ently reported in the prevalence of comorbid conditions in 
adults with ADHD. Specifically, SUD (alcohol use), conduct 
disorder (CD), antisocial PD were more prevalent among 
males, while MD, dysthymia, and anxiety disorders were 
more prevalent among females with ADHD in the majority 
of the studies (Biederman et al. 1993; Sobanski et al. 2007; 
Sprafkin et al. 2007; Wilens et al. 2009). Nonetheless, Bie-
derman (2004) reported on no moderating effect of gender 
on psychiatric comorbidity with ADHD in adults.
Other possible moderating factors for the rate of comor-
bidity in/with ADHD could be the severity of ADHD and 
the diagnostic criteria used for ADHD (Bitter et al. 2010). 
This has been supported by the findings indicating that 
ADHD symptom severity is significantly correlated with the 
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Fig. 1  Study flowchart, basic demographics and raw prevalence rates by patient disposition
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occurrence of lifetime depressive episodes in both males and 
females (Simon et al. 2013).
Our data underline the need for better training for the 
recognition of adult ADHD comorbid with substance use 
and other mental disorders.
Limitations
The major limitation of this study is its cross-sec-
tional design, which does not permit to establish causal 
relationships.
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